Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation (PRCT) delivers pioneering surgical robotics solutions for urologic care, with its AquaBeam and HYDROS systems redefining minimally invasive BPH treatment. This news hub provides investors and medical professionals with essential updates on PRCT's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative updates including FDA clearances, peer-reviewed study results, and financial performance reports. Our curated collection features official press releases on product innovations, partnership announcements, and clinical trial outcomes backed by PRCT's extensive clinical evidence base.
Stay informed about developments in aquablation therapy technology, global market expansion efforts, and advancements in AI-driven surgical planning. Content spans regulatory filings, executive leadership updates, and analyses of PRCT's growing body of clinical validation across urologic applications.
Bookmark this page for streamlined access to PROCEPT BioRobotics' latest achievements in surgical robotics. Check regularly for verified updates on technologies improving patient outcomes through precision tissue resection and image-guided procedures.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) reported strong financial results for Q1 2023, with total revenue of $24.4 million, up 72% year-over-year. U.S. handpiece and consumables revenue surged 165% to $11.8 million, while system and rental revenue increased 13% to $8.8 million. The company raised its 2023 revenue guidance to $128 million, a 71% growth from the previous year. PROCEPT also received a positive coverage policy from United Healthcare and signed a national sales contract with a significant U.S. integrated delivery network.
Despite these gains, the net loss widened to $28.5 million from $17.2 million in the prior year. Operating expenses rose to $40.9 million, reflecting increased sales and marketing investments. Gross margin decreased to 51% from 54%.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced it will report its financial results for Q1 2023 on April 27, 2023, before market open. A conference call is scheduled for the same day at 8:00 a.m. Eastern Time. The company is focused on innovations in urology and has developed the AquaBeam Robotic System for minimally invasive surgeries to treat benign prostatic hyperplasia (BPH), affecting about 40 million men in the U.S. PROCEPT BioRobotics emphasizes the effectiveness and safety of its Aquablation therapy, supported by a substantial clinical evidence base, including nine studies and over 150 peer-reviewed publications. Additionally, management will present at the Bank of America 2023 Health Care Conference on May 10, 2023.
PROCEPT BioRobotics Corporation (PRCT) announced that United Healthcare updated its Prostate Surgeries and Interventions Policy Bulletin, confirming Aquablation therapy as medically necessary for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Effective June 1, 2023, this policy enhances accessibility for patients, potentially providing access to approximately 95% of men in the U.S. The Aquablation therapy employs an automated robotic system that uses heat-free waterjet technology, backed by successful FDA trials demonstrating its safety and efficacy.
